Kiniksa Pharmaceuticals International (KNSA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

KNSA Kiniksa Pharmaceuticals International

Watchlist

19.740
+0.090+0.46%

Close Feb 14 16:00 ET

19.740
0.0000.00%

Post 16:20 ET

1.43BMarket Cap-164.50P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Sale: CHIEF OPERATING OFFICER of $KNSA Sells 14,000 Shares
Quiver QuantitativeFeb 12 17:03 ET
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35
Moomoo NewsFeb 4 01:32 ET · Ratings
12 Health Care Stocks Moving In Thursday's Pre-Market Session
BenzingaJan 30 07:07 ET
Trending Stocks Today | Vision Marine Technologies Shoots up 30% Post-Market
Moomoo NewsJan 14 18:00 ET
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32
Moomoo NewsJan 13 14:31 ET · Ratings
Kiniksa Pharma Reports Q4 ARCALYST Revenue Of $121.9M, Cash Balance Of $243.6M
BenzingaJan 13 07:40 ET

Comments

TrendTrader

Jul 23, 2024 11:19

Looking for 30

$Kiniksa Pharmaceuticals International (KNSA.US)$

Moomoo AI

Feb 28, 2024 07:16

The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Moomoo AI

Jan 23, 2024 06:38

Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.

Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Low P/S No Reason For Excitement

Meltyy

Jan 3, 2024 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Dec 8, 2023 10:12

Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

KNSA Kiniksa Pharmaceuticals International

Trade Overview

Capital Trend

News

Comments

Trending Stocks